Amino Acid IV Therapy: Mechanism, Evidence and Why the Verdict Changes by Molecule

In short: amino acid IV therapy is not one intervention but several, and the evidence splits sharply by molecule, dose and setting. In critically ill adults, glutamine infusion was linked to a trend toward higher 28-day mortality and significantly higher hospital and six-month mortality in a 1,223-patient trial (REDOXS) — a signal that pushed ASPEN and ESPEN toward guidance against routine glutamine outside burn care. In the same broad population — cardiac surgery — a balanced amino acid infusion at a defined, monitored dose reduced acute kidney injury in a 3,511-patient trial (PROTECTION) published in 2024. Arginine and ornithine have a genuine, narrow evidence base of their own in liver disease. Taurine's 2023 anti-aging headline was substantially undercut by two independent 2025 studies. None of the trials behind any of this evidence used the small, unmonitored doses sold in a wellness amino acid drip, and none tested a healthy adult seeking a "longevity" benefit — the honest read of this category is indication-specific, not molecule-wide.

No compound category in this Journal has a more divided evidence record than amino acids. The same broad group that produced one of intensive care medicine's clearest signals of harm has, in a separate trial population, produced one of its more convincing recent wins. That split is not two research teams reaching different conclusions about the same thing — it reflects genuinely different molecules, doses and patients, folded into a single marketing label. Reading an amino acid formulation honestly means pulling that label apart before asking whether "it" works.

What "amino acid IV therapy" actually means

Three distinct things share this name. The first is parenteral nutrition: FDA-approved amino acid solutions — products such as Travasol, Aminosyn and Clinisol — indicated for patients who cannot meet protein requirements enterally, dosed by body weight and nitrogen balance, and administered under medical supervision as part of total parenteral nutrition. This is old, uncontroversial medicine.

The second is a narrower and much newer category: a balanced amino acid infusion given at a defined dose, over a defined window, to a specific surgical population, tested against placebo for a specific outcome. The 2024 PROTECTION trial — 3,511 adults undergoing cardiac surgery with cardiopulmonary bypass across 22 centres in three countries — is the clearest example: up to 2 g/kg of ideal body weight per day for three days, reducing acute kidney injury from 31.5% to 26.9% (relative risk 0.85). That is a real, monitored, hospital-administered intervention with a specific mechanism hypothesis — amino acid infusion increases renal blood flow and glomerular filtration — tested in the population where it plausibly matters.

The third is what most people mean when they ask about it: a wellness-clinic blend of glutamine, arginine, glycine, taurine, ornithine and methionine in a peripheral IV, marketed for recovery, detoxification, "methylation support" or anti-aging, at doses and in a population — healthy, non-catabolic adults — that essentially none of the amino acid trial literature has ever tested. Formulations like this borrow the credibility of the first two categories while being evaluated by neither.

What changes when you bypass the gut

Dietary amino acids do not reach systemic circulation unmodified. They are absorbed by a shared, saturable set of intestinal transporters, and a meaningful share is extracted by the gut wall and liver before the rest reaches peripheral blood — glutamine in particular is a preferred fuel for enterocytes and immune cells lining the gut, so a large fraction of an oral or enteral dose is consumed locally rather than delivered systemically. An intravenous infusion skips all of that: the full dose reaches the bloodstream at once, at a rate the clinician controls.

That is precisely the property researchers were testing in both directions. The rationale for glutamine in critical illness was that gut and immune cells become "conditionally essential" consumers of glutamine during severe illness, and that IV delivery could supply what oral intake could not. The rationale for the PROTECTION trial was that a large, controlled amino acid load increases renal blood flow and single-nephron filtration during the highest-risk window of cardiac surgery — an effect that requires exactly the kind of bolus-and-sustain dosing only an infusion can deliver.

The same property that makes IV amino acids capable of a measurable benefit in a defined clinical scenario is what makes an unmonitored, higher-than-dietary dose capable of a measurable harm in a different one. Bypassing the gut removes a regulatory step, not just a delay — which is the throughline connecting the next four sections.

Glutamine: the cautionary trial

Glutamine looked, on paper, like the strongest candidate in this category. It is the most abundant free amino acid in the body, becomes conditionally essential during critical illness, and small earlier trials suggested a survival benefit when delivered parenterally to ICU patients. REDOXS was designed to confirm that at scale: 1,223 mechanically ventilated adults with multi-organ failure across 40 ICUs in Canada, the United States and Europe, randomised in a 2×2 factorial design to glutamine, antioxidants, both or neither, given both intravenously and enterally.

The result reversed the hypothesis. Glutamine was associated with a trend toward higher 28-day mortality and with significantly higher in-hospital and six-month mortality — the first large trial to demonstrate harm from glutamine supplementation in critical illness, with the signal appearing strongest among patients who had baseline renal dysfunction. A second large trial, MetaPlus, tested enteral high-protein nutrition enriched with glutamine and other immune-modulating nutrients against standard high-protein nutrition and found no reduction in infections.

Guideline bodies moved accordingly. The 2016 ASPEN/SCCM critical-care guideline recommends against routinely adding supplemental glutamine to enteral nutrition in general ICU patients. ESPEN's 2023 revision goes further for the intravenous route specifically: parenteral glutamine is no longer part of standard parenteral nutrition for stability reasons, and enteral glutamine is reserved for one narrow exception — burn patients with more than 20% body surface area involvement, at 0.3 to 0.5 g/kg per day for 10 to 15 days. Outside that indication, the guidance is not neutral; it is a recommendation against use.

Arginine, ornithine and the ammonia axis

Arginine and ornithine share a metabolic pathway — the urea cycle — and a similarly narrow, indication-specific evidence base. Ornithine's clearest clinical role is paired with aspartate as L-ornithine L-aspartate (LOLA), which accelerates ammonia disposal via the urea cycle and glutamine synthesis. The pivotal trial behind current AASLD-EASL guidance on overt hepatic encephalopathy is a single placebo-controlled, double-blind study: intravenous LOLA in cirrhotic patients with hepatic encephalopathy, which improved venous ammonia and mental state scores against placebo. Guideline bodies describe the recommendation as resting on that one randomised trial — a real effect, in a specific, ammonia-driven condition, that does not generalise to a healthy person's ornithine dose.

Arginine's history is more cautionary. Enteral "immunonutrition" formulas combining arginine with omega-3 fatty acids and nucleotides were studied through the 1990s and 2000s on the hypothesis that arginine boosts nitric oxide production and immune function after surgery or trauma. In septic and critically ill patients specifically, that same nitric-oxide mechanism raised the opposite concern — excess arginine could worsen vasodilation and hypotension in sepsis — and both the ASPEN/SCCM and ESPEN critical-care guidelines caution against arginine-containing immune-modulating formulas in septic ICU patients while allowing more latitude in elective surgical populations. None of this literature is intravenous wellness dosing, and none of it describes a healthy adult.

Glycine, taurine and the longevity claims

This is where the category's most-cited "anti-aging" evidence lives, and where its most instructive reversal happened. GlyNAC — glycine combined with N-acetylcysteine to raise intracellular glutathione — has one real human trial behind it: a placebo-controlled, 16-week study in 24 older adults, comparing GlyNAC against an isonitrogenous alanine placebo. It reported improvements in glutathione status, oxidative stress markers, mitochondrial function, inflammation, muscle strength and gait speed relative to placebo. That is a genuine, randomised signal — and also a single pilot trial in 24 people, taken orally, not infused, that has not yet been replicated at scale.

Taurine's trajectory is the sharper lesson. In June 2023, a large multi-species study in Science reported that circulating taurine declines with age in humans, mice and monkeys, and that taurine supplementation extended healthy lifespan in mice by up to 12% — the paper behind most "taurine and longevity" marketing since. In June 2025, a separate NIH-led team published a direct challenge in the same journal: longitudinal and cross-sectional taurine measurements across three geographically distinct human cohorts, plus non-human primates and mice, found taurine concentrations were stable or increased with age, not declining, and varied more by individual, diet and species than by age itself. A second independent 2025 study in Aging Cell reached a similar conclusion, finding little support for taurine deficiency as a driver of human aging.

Both papers can be correct in the sense that neither disproves a possible therapeutic effect of taurine at a given dose — what the 2025 work undermines specifically is the premise that taurine falls with age and that restoring it corrects a deficiency. That premise, not a therapeutic claim, is what most consumer taurine marketing has actually been selling. Two years after the original headline, the field's own literature has not settled the question in either direction — a materially different, more honest position than the 2023 story alone suggested.

Methionine: infusing what longevity research restricts

Methionine sits awkwardly in an anti-aging formulation for a specific reason: the strongest lifespan-extension literature involving this amino acid is about restricting it, not adding it. Dietary methionine restriction — typically an 80% or greater reduction in rodent chow — has repeatedly extended lifespan and improved metabolic markers across multiple animal models since the 1990s, through mechanisms overlapping with caloric restriction: reduced IGF-1 signalling, improved insulin sensitivity, altered one-carbon metabolism. Small human trials of methionine restriction show metabolic improvements over weeks to months, though nothing at the scale of the animal lifespan data.

None of that literature tests the opposite intervention — infusing supplemental methionine into a healthy adult — and none of it would predict a benefit from doing so. Methionine also converts to homocysteine, the same intermediate implicated in the B12 and folate methylation cycle discussed elsewhere in this Journal; adding methionine without the cofactors that clear it is, at minimum, metabolically inconsistent with a "longevity support" framing. This is not a molecule with a documented IV safety signal like glutamine — it is a molecule whose only substantial aging-related evidence points the opposite direction from the product category it is sold in.

Clinical evidence graded by indication and route

Read across the six molecules together, the pattern in the table below is less about amino acids as a class and more about how narrowly indication-specific the positive evidence actually is.

Two things generalise across every row that has real support: the dose and the population were controlled, and the outcome measured was a hard clinical endpoint — kidney injury, ammonia-driven encephalopathy, documented deficiency — not a subjective wellness measure. Neither condition holds for a self-administered or walk-in amino acid drip in a healthy adult.

How to read an amino acid formulation

Assessing an amino acid IV formulation means asking the same three-part question this Journal applies elsewhere: what is the indication, what is the dose relative to the trials that actually tested it, and is the population being marketed to the population that was studied? Glutamine in a general wellness blend, at a gram-scale dose, sold to a healthy adult, sits closest to the population REDOXS studied and found harm in — not the burn population ESPEN still supports. Arginine and ornithine sit closest to their genuine indications only when the product is aimed at ammonia-related or perioperative contexts, which a consumer wellness drip is not.

The Power Amino Mix concept — glutamine, arginine, ornithine, methionine and glycine — and adjacent amino-acid formulations such as the collagen-support concept built on proline, lysine and carnosine, are formulation-completeness products in the same sense as the glutathione line discussed elsewhere in this Journal: built around ingredients with genuine, if narrow, clinical pedigrees, at doses designed for a wellness context rather than to replicate a hospital protocol. That distinction — which trial supports which dose, in which patient — is the standard EFBA applies across the amino acid range, and it is the one question the marketing for this category rarely survives being asked.